Celgene Corporation

Celgene — Merger or Acquisition (January 2018)

23 slides from Celgene's merger presentation, Jan 22, 2018

  1. Slide 1: Celgene Announces Acquisition of Juno Therapeutics

    Celgene Announces Acquisition of Juno Therapeutics January 22, 2018 C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE

  2. Slide 2: Forward Looking Statements and Adjusted Financial Information

    Forward Looking Statements and Adjusted Financial Information Thi s presentatio n contain s forward - lookin g statements , whic h ar e generall y s tatement s tha t ar e not historica l facts . Forward - lookin g s tatement s ca n b e identifie d b y th e word s “ expects, ” “anticipates,” “believe

  3. Slide 3: Additional Information on the Tender Offer

    Additional Information on the Tender Offer The tender offer described herein has not yet commenced. The description contained herein is for informational purposes only an d is not an offer to buy or the solicitation of an offer to sell any shares of Juno Therapeutics, Inc. (Juno). At the time the te

  4. Slide 4: Mark Alles, Chief Executive Officer

    Mark Alles Chief Executive Officer C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE

  5. Slide 5: Our Mission and Vision

    Our Mission and Vision Celgene is building a preeminent global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for patients with cancer, immune - inflammatory, and other unmet medical needs

  6. Slide 6: Cellular Immunotherapy Is a Validated Approach with Vast Potential

    2011 2012 2013 2014 2015 2016 2017 2018 Expected Near - Term Value Drivers Cellular Immunotherapy Is a Validated Approach and Has Vast Potential to Become a Standard Component of Cancer Care First CAR T Data Demonstrating Technical POC First CAR T Therapies Approved for R/R ALL and R/R DLBCL BCMA Cl

  7. Slide 7: There Are Significant Advantages in Acquiring Juno Now

    There Are Significant Advantages in Acquiring Juno Now x Near - term pipeline is complementary with our existing Hematology & Oncology portfolio x JCAR017 clinical data supports a potentially best - in - class profile providing an anchor therapy in NHL x JCARH125 adds to our campaign against BCMA, a

  8. Slide 8: Celgene Well Positioned to Become a Preeminent Cellular Immunotherapy Company

    Celgene Will Be Well Positioned to Become a Preeminent Cellular Immunotherapy Company x Deep global Hematology & Oncology clinical and regulatory expertise x Global commercial reach x Complementary pipeline with potentially synergistic next - generation I/O assets x 15+ year history with GMP manufac

  9. Slide 9: Robert Hershberg, EVP, Head of Business Development

    Robert Hershberg, MD, PhD EVP, Head of Business Development C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE

  10. Slide 10: Juno's Cellular Immunotherapy Platform Drives the Emerging Pipeline

    Juno’s Powerful Cellular Immunotherapy Platform, Established Relationships and Approach Drives the Emerging Pipeline CAR T Technology: recognizes proteins on the surface of cancer cells TCR Technology: recognizes intracellular tumor - specific proteins Cellular Immunotherapy Established Relationship

  11. Slide 11: Celgene Scientifically Positioned to Optimize Cellular Immunotherapy

    Celgene Is Scientifically Positioned to Optimize Cellular Immunotherapy Given Its Broad & Diverse I/O Capability • BCMA CAR T (bb2121/bb21217) • Anti - PD1 (BGB - A317) for solid tumors Celgene’s Mid - to - Late Stage I/O Assets CAR T TCR Juno’s Clinical Stage Cellular Immunotherapy • CD19 (JCAR017)

  12. Slide 12: Celgene's Translational Science Capabilities

    Immune cell phenotyping by flow and mass cytometry Antibody profiling by protein and peptide microarray Gene expression profiling by RNA sequencing and microarray Immune cell metabolic profiling by metabolomics Cytokine, chemokine, soluble factors analysis by Mesoscale and Luminex TCR and Ig reperto

  13. Slide 13: JCARH125 Will Add to Our Campaign Against BCMA

    JCARH125 Will Add to Our Campaign Against BCMA – A Key Target in Multiple Myeloma CAR T Cells TUMOR 3 . Antibody Drug Conjugate BCMA T Cells 2 . T Cell Engager Antibody BCMA 1. CAR T Therapy BCMA TCR Cytotoxic granules Cytotoxic granules Robust Multi - Modal Campaign Against BCMA T Cell Engager Anti

  14. Slide 14: Nadim Ahmed, President, Hematology & Oncology

    Nadim Ahmed President, Hematology & Oncology C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE

  15. Slide 15: Juno's Pipeline Will Expand and Complement Celgene's Opportunities

    0 0.5 1 1.5 2 2.5 3 3.5 LeY JCAR024 (ROR1) JCAR020 (MUC16/IL-12) JCAR023 (L1CAM) JTCR016 (WT1) JCARH125 (BCMA) JCAR018 (CD22) JCAR017 (CD19) NHL, CLL Pediatric ALL MM AML, NSCLC Pediatric Neuroblastoma Ovarian NSCLC, Breast Solid Tumors Phase I Preclinical Pivotal Market Ph I LEGEND Juno’s Pipeline

  16. Slide 16: JCAR017 – Emerging Favorable Profile in R/R DLBCL

    JCAR017 – Emerging Favorable Profile in R/R DLBCL Data include: JCAR017 CORE R/R DLBCL Phase I for both DL1S and DL2S groups (safety n=67; efficacy n=65 data cut - off October 9, 2017, ASH 2017); YESCARTA™ Phase II (n=101, ASCO 2017); and, KYMRIAH™ Phase II (safety n=99, efficacy n=46 ASH 2017). Dat

  17. Slide 17: Broad Clinical Development Plan for JCAR017

    Broad Clinical Development Plan in Place to Maximize JCAR017’s Clinical and Commercial Potential Phase I/II TRANSCEND (3 rd line with outpatient cohort) Initiate Phase II TRANSCEND WORLD Initiate Phase II PILOT (2 nd line non - transplant eligible) Initiate Phase III TRANSFORM (2 nd line transplant

  18. Slide 18: JCAR017 a Potential Foundational Therapy in Non-Hodgkin Lymphoma

    JCAR017 Represents a Potential Foundational Therapy to Establish Global Leadership in Non - Hodgkin Lymphoma Note: REVLIMID ® is not approved for follicular or diffuse Large B - cell non - Hodgkin lymphoma CDx: companion diagnostic Diffuse Large B - cell Lymphoma Follicular Lymphoma Induction ABC UC

  19. Slide 19: Peter Kellogg, Chief Financial Officer

    Peter Kellogg Chief Financial Officer C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE

  20. Slide 20: Transaction Overview

    Transaction Overview • All - cash consideration of $87 per share • Total transaction value of $9 billion, net of cash / marketable securities and Celgene ownership • Strong combined balance sheet • Resulting capital structure consistent with financial strategy and investment grade profile • Transact

  21. Slide 21: Scott Smith, President & Chief Operating Officer

    Scott Smith President & Chief Operating Officer C HANGING THE C OURSE OF H UMAN H EALTH T HROUGH B OLD P URSUITS IN S CIENCE

  22. Slide 22: Delivering Industry-Leading Growth Through 2020 and Beyond

    Delivering Industry - Leading Growth Through 2020… Late - stage Pipeline with Potential to Add Over $16B in Incremental Peak Revenue Through 2030 …And Positioned to Grow Beyond 2020 JCAR017 CC - 220 CC - 486 Luspatercept Marizomib CC - 122 bb2121 BGB - A317 Fedratinib Ozanimod Expected to Launch Ten

  23. Slide 23: Building a Preeminent Cellular Immunotherapy Company

    ▪ Additive to 2020 revenue; no change to 2020 adjusted EPS ▪ Potentially best - in - class JCAR017 provides anchor position in NHL Building a Preeminent Cellular Immunotherapy Company Execute Delivering on 2020 Accelerate Positioning to Grow Beyond 2020 Expand Creating Sustainable Growth ▪ Accelerat

Celgene — Merger or Acquisition (January 2018) on 6ix